Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

What to do with IL-2?

¹Hoag Cancer Center, Newport Beach, California 92658-6100, USA. www.hoag.org

Cancer Biotherapy & Radiopharmaceuticals

|June 13, 2000

Summary

This summary is machine-generated.

Interleukin-2 (IL-2) is a standard cancer treatment for melanoma and renal cell carcinoma. However, optimal dosing and administration methods remain debated, with combination therapies not improving long-term survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial.

Journal of biomedicine & biotechnology·2011

Same author

Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival.

Cancer immunology, immunotherapy : CII·2010

Same author

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.

Clinical and experimental medicine·2006

Same author

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

Annals of oncology : official journal of the European Society for Medical Oncology·2004

Same author

How can we improve survival rate for patients with non-small-cell lung cancer?

Clinical lung cancer·2004

Same author

Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2003

Area of Science:

Immunotherapy
Oncology
Pharmacology

Background:

Interleukin-2 (IL-2) has been clinically utilized for 15 years.
IL-2 is approved for metastatic melanoma and renal cell carcinoma in various forms.
Current treatment involves high-dose bolus, moderate-dose continuous infusion, or low-dose outpatient IL-2.

Purpose of the Study:

To review the current status and optimal administration of Interleukin-2 (IL-2) in cancer therapy.
To discuss the risk-benefit profile of different IL-2 dosing and scheduling strategies.
To evaluate the efficacy of IL-2 in combination with chemotherapy or biotherapy.

Main Methods:

Review of clinical reports and treatment guidelines for IL-2 therapy.
Analysis of data regarding different IL-2 administration schedules (bolus, infusion, outpatient).

Related Experiment Videos

Comparison of IL-2 monotherapy versus combination regimens with chemotherapy and interferon.

Main Results:

IL-2 is an established treatment for metastatic melanoma and renal cell carcinoma.
Multiple IL-2 delivery methods are in use, but no consensus exists on the optimal approach.
Combination therapies with chemotherapy/interferon show higher response rates but not improved long-term survival.

Conclusions:

The optimal risk-benefit balance for IL-2 administration requires further investigation.
Despite varied administration methods, long-term survival benefits from IL-2 combination therapies are not yet established.
Further research is needed to define the best IL-2 treatment protocols for maximizing patient outcomes.